Sunshine Biopharma (SBFM) Liabilities and Shareholders Equity (2010 - 2026)

Sunshine Biopharma has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $27.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 4.31% year-over-year to $27.9 million; the trailing twelve-month figure through Mar 2026 stood at $121.5 million (up 1.98% YoY), and the FY2025 full-year result was $30.1 million, down 1.57% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $27.9 million, down from $30.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $42.0 million in Q2 2022, with the low at $13.4 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $29.9 million across 5 years, with a median of $29.3 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 2210.92% — and 2023, when it slumped 32.34%.
• Sunshine Biopharma's Liabilities and Shareholders Equity stood at $29.2 million in 2022, then declined by 6.49% to $27.3 million in 2023, then gained by 11.75% to $30.6 million in 2024, then declined by 1.57% to $30.1 million in 2025, then fell by 7.14% to $27.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $27.9 million (Q1 2026), $30.1 million (Q4 2025), and $31.5 million (Q3 2025), per Business Quant data.